Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Parand Darou Oxycodone Hydrochloride

    Virtual Booth

    Contact Supplier

    Temad Oxycodone Hydrochloride

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Faran Shimi Oxycodone

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Oxycodone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,540Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Tris shows its opioid alternative is less likely to be abused
    Tris shows its opioid alternative is less likely to be abused

    28 Jan 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/tris-builds-clinical-case-opioid-alternative-showing-pain-drug-less-likely-be-abused

    FIERCE BIOTECH
    28 Jan 2025
    Share Share
    Scilex To File Supplemental NDA With FDA For Elyxyb Acute Pain
    Scilex To File Supplemental NDA With FDA For Elyxyb Acute Pain

    21 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/21/3012506/0/en/Scilex-Holding-Company-Announces-that-It-Will-Be-Filing-Today-of-a-Supplemental-New-Drug-Application-with-the-FDA-for-ELYXYB-in-Acute-Pain-Indication.html

    GLOBENEWSWIRE
    21 Jan 2025
    Share Share
    Protega Gets Fda Approval For RoxyBond™ Abuse-Deterrent Pain Med
    Protega Gets Fda Approval For RoxyBond™ Abuse-Deterrent Pain Med

    29 Oct 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/protega-pharmaceuticals-receives-fda-approval-for-roxybond-oxycodone-hydrochloride-immediate-release-10-mg-tablet-with-abuse-deterrent-technology-for-management-of-pain-302289975.html

    PR NEWSWIRE
    29 Oct 2024
    Share Share
    Enforcement Report - Week of November 15, 2023
    Enforcement Report - Week of November 15, 2023

    15 Nov 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-november-15-2023-17266.pdf

    FDA
    15 Nov 2023
    Share Share
    Adapted SynNotch, A New Generation Of Flexible And Controllable CAR T Therapies
    Adapted SynNotch, A New Generation Of Flexible And Controllable CAR T Therapies

    30 May 2023

    // William A. Haseltine FORBES

    https://www.forbes.com/sites/williamhaseltine/2023/05/30/adapted-synnotch-a-new-generation-of-flexible-and-controllable-car-t-therapies-part-3/?sh=5a281fdd4a63

    William A. Haseltine FORBES
    30 May 2023
    Share Share
    US fentanyl-related deaths more than tripled over 5 years
    US fentanyl-related deaths more than tripled over 5 years

    03 May 2023

    // Nandhini Srinivasan REUTERS

    https://www.reuters.com/world/us/us-fentanyl-related-deaths-more-than-tripled-over-5-years-2023-05-03/

    Nandhini Srinivasan REUTERS
    03 May 2023
    Share Share